SubsidieMeestersMacrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Projectdetails
Introduction
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer. About 300,000 women are diagnosed with ovarian cancer each year, and the number of deaths is estimated at 180,000 worldwide annually. Ovarian cancer metastasizes early in its development, often before it's diagnosed.
Treatment Overview
Ovarian cancer treatment involves surgery with frontline platinum-based chemotherapy. As many as 15-30% of patients with ovarian cancer have primary platinum-resistant or refractory disease. The recurrence of ovarian cancer is now considered a sign of an incurable disease, as it becomes platinum-resistant.
Project Description
The project MACOV aims to develop an innovative allogeneic, “ready-to-use” macrophage-based therapy for platinum-resistant ovarian cancer. This is a ground-breaking, first-in-class therapy that shows very high efficacy in multiple solid tumors of unmet medical need.
Mechanism of Action
These cells are equipped with targeted therapy drugs complexed with the carrier protein, ensuring their stability in the carrier cell. The protein-drug complex is transferred specifically to cancer cells. The whole concept of this cell therapy is based on the groundbreaking scientific discoveries of MDC (Macrophage-Drug Conjugate).
Research Grants and Recognition
Two European Research Council (ERC) grants were received to study the molecular basis of the discovered mechanism in 2016 and 2020. In 2018, this project was selected to be promoted as one of the 10 European projects during the ERC 10th Anniversary.
Project Goals
The MACOV project will generate a complete efficacy data package for the pre-clinical development of the MDC-735 product, which includes:
- Efficacy in multiple animal models for platinum-resistant ovarian cancer
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)
- Toxicology study
- Consolidation of intellectual property (IP)
- Validation of the business case
Expected Outcomes
The result of the project will be a validated cell therapy product for platinum-refractory ovarian cancer, tested for effectiveness and ready-to-use for the Phase I clinical trial.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.998 |
| Totale projectbegroting | € 2.499.998 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CELLIS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Allogeneic Macrophages for Cancer TherapyONCOMAC aims to prepare a preclinical proof-of-concept study for genetically engineered human macrophages as a novel cancer cell therapy, ensuring compliance with regulatory standards for clinical trials. | ERC POC | € 150.000 | 2022 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC POC | € 150.000 | 2022 | Details |
Achieving the golden Grail in solid tumor treatmentThe McHAP project aims to commercialize Macrophage-Drug Conjugates for solid tumor treatment by confirming tumor-resistance mechanisms and optimizing immune responses for clinical application. | ERC POC | € 150.000 | 2023 | Details |
Ruthenium-containing Polymers against Ovarian CancersThis project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance. | ERC POC | € 150.000 | 2023 | Details |
Allogeneic Macrophages for Cancer Therapy
ONCOMAC aims to prepare a preclinical proof-of-concept study for genetically engineered human macrophages as a novel cancer cell therapy, ensuring compliance with regulatory standards for clinical trials.
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Achieving the golden Grail in solid tumor treatment
The McHAP project aims to commercialize Macrophage-Drug Conjugates for solid tumor treatment by confirming tumor-resistance mechanisms and optimizing immune responses for clinical application.
Ruthenium-containing Polymers against Ovarian Cancers
This project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance.